# Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

> **NCT06370871** · PHASE3 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Advanced Soft Tissue Sarcoma
- Undifferentiated Pleomorphic Sarcoma (UPS)
- Myxofibrosarcoma (MFS)

## Interventions

- **DRUG:** Brigimadlin
- **DRUG:** Ezabenlimab
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06370871
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-27
- **Primary completion:** 2026-07-03
- **Final completion:** 2028-10-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370871, "Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06370871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*